 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Saint Herblain (France), September 25, 2023 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United...

Valneva Announces New IXIARO  Supply Contract with the U.S. Government Worth a Minimum of $32 Million

Product sales more than doubled in the first half of 2023 to 69.7 million compared to 33.3 million in the first half of 2022 Driven by IXIARO and DUKORAL sales, both of which benefited from a...

Valneva Reports Half Year 2023 Financial Results and  Provides Corporate Updates

Strong immune response shown in both children and adolescents one month after booster dose (month 19) in VLA15-221 studyPreviously observed high anamnestic antibody response in adults confirmedVLA15...

Valneva and Pfizer Report Positive Pediatric and Adolescent  Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Valneva SE (NASDAQ:VALN  Get Free Report) was the recipient of a large drop in short interest in August. As of August 15th, there was short interest totalling 5,400 shares, a drop of 25.0...

Short Interest in Valneva SE (NASDAQ:VALN) Decreases By 25.0%

Saint-Herblain (France), August 29, 2023 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has completed screening validation of the Companys regulatory application for marketing approval of its single-shot chikungunya vaccine candidate ...

Health Canada Accepts Valneva's Chikungunya Vaccine License Application for Review

Saint-Herblain (France), August 28, 2023 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive initial Phase 3 safety data in adolescents for its...

Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

Up to an additional $100 million made available in two tranches Saint-Herblain (France), August 17, 2023 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement to increase the principal amount of its existing $100 million senior secured debt ...

Valneva Announces Extension of Existing Loan Agreement

In trading on Wednesday, shares of Valneva SE (VALN) crossed below their 200 day moving average of 13.13, changing hands as low as 13.10 per share. Valneva SE shares are currently trading off about 0.9% on the day...

Notable Two Hundred Day Moving Average Cross - VALN

Saint-Herblain (France), August 14, 2023 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has revised...

Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate

Saint-Herblain (France), June 22, 2023 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its Supervisory Board has recommended a change of governance model. The Companys Supervisory Board members voted in favor of recommending to the shareholders to ...

Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors

Valneva SE is a specialty vaccine company. The firm focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. It takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. It operates through the following segments: Commercialized products, COVID, Vaccine candidates and Technologies and services. The Commercialized products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment engages in the development, manufacturing and distribution related to COVID-19 vaccine candidate, VLA2001. The Vaccine candidates segment engages in proprietary research and development programs aiming to generate new approvable products in order to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies, excluding COVID-19 vaccine candidate, VLA2001. The Technologies and services segment provides services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Watchers	2,113
52-Wk Low	$9.07
52-Wk High	$17.05

Market Cap	$803.49M
Volume (M)	5,990.00
52-Wk High	$17.05
52-Wk Low	$9.07

VALN Valneva SE - ADR

About

Feed

News

Earnings

Fundamentals